Machine Intelligence Research Institute

Verana Health Partners with Foundation Fighting Blindness to Integrate Genetic Testing Data into Real-World Evidence Research

Retrieved on: 
星期四, 十一月 2, 2023
Health Technology, Data Management, Other Health, Technology, Optical, General Health, Professional Services, Philanthropy, Genetics, Clinical Trials, Foundation, Biotechnology, Science, Data Analytics, Research, Health, Genetic testing, IRIS, Biomarker, Ophthalmology, Foundation Fighting Blindness, Data, RWE, Visual impairment, Genomics, Medicine, American Academy, Machine Intelligence Research Institute, Retina, American Academy of Ophthalmology, Partnership, Patient, Pharmaceutical industry, Nursing

Under the partnership, the Foundation will provide Verana with de-identified genomics data from its My Retina Tracker® Registry to support clinical research surrounding patients with inherited retinal degenerative diseases.

Key Points: 
  • Under the partnership, the Foundation will provide Verana with de-identified genomics data from its My Retina Tracker® Registry to support clinical research surrounding patients with inherited retinal degenerative diseases.
  • This groundbreaking partnership leverages the Foundation’s de-identified genomics and patient-reported data on tens of thousands of individuals with inherited retinal degenerative diseases to support commercial real-world evidence (RWE) clinical research initiatives.
  • As part of its mission to drive the research that will provide preventions, treatments and cures for people affected by retinal degenerative diseases, the Foundation Fighting Blindness provides no-cost genetic testing to people with inherited retinal diseases.
  • Through its partnership with the Foundation Fighting Blindness, Verana will be able to incorporate the Foundation’s detailed genomics and patient-reported data, along with IRIS Registry data, into its client-facing clinical research initiatives.

Verana Health Launches Real-World Evidence-Driven Solution for Clinical Trial Site Selection

Retrieved on: 
星期四, 六月 22, 2023
Professional Services, Health, Data Analytics, Health Technology, Other Health, Clinical Trials, Biotechnology, Natural language processing, Failure, Clinical trial, American Academy, Medicine, RWD, Machine Intelligence Research Institute, Organization, Intraocular pressure, Ophthalmology, Patient, Data, EHR, Machine learning, Artificial intelligence, Diagnosis, Visual acuity, ChromeOS, Pharmaceutical industry, Medical imaging

Verana Health ®—a digital health company elevating quality in real-world data (RWD)—today announced the launch of VeraSite, a solution for identifying potential clinical trial sites.

Key Points: 
  • Verana Health ®—a digital health company elevating quality in real-world data (RWD)—today announced the launch of VeraSite, a solution for identifying potential clinical trial sites.
  • This data can guide site selection, ensuring sponsors and CROs are selecting sites that better align with study goals.
  • Verana Health can also reach out to consenting practices on the sponsor’s behalf to make introductions, expanding access to new patient populations.
  • Additional site-level information, such as trial experience, sub-specialties and clinical areas of interest, are used to match investigators to upcoming clinical trials.

Allen Institute for Artificial Intelligence (AI2) Announces New CEO

Retrieved on: 
星期二, 六月 20, 2023
Machine Intelligence Research Institute, Sloan Research Fellowship, University, Engineering, NSF, University of Washington, Intelligence, Microsoft, Research, Science, Computer vision, CVPR, Machine learning, Algorithm, AI2, National Science Foundation CAREER Award, Artificial intelligence, Deep learning, AI, Farhadi (surname), AAAI, Computer science, Allen Institute, Medical device, Apple

SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- The Allen Institute for Artificial Intelligence (AI2) today announced Ali Farhadi will become its new Chief Executive Officer, effective July 31.

Key Points: 
  • SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- The Allen Institute for Artificial Intelligence (AI2) today announced Ali Farhadi will become its new Chief Executive Officer, effective July 31.
  • Founded in 2014, AI2 is the research institute created by the late philanthropist Paul G. Allen, co-founder of Microsoft, to drive high-impact AI research and engineering.
  • The 501(c)3 nonprofit organization has been responsible for a number of groundbreaking advancements in AI and continues to be a leader in generative and foundational AI research.
  • “As the premier AI research and engineering nonprofit, AI2’s work to advance the science and impact of artificial intelligence on a global scale has never been more critical.

Aviso AI Unveils First Generative AI Designed to be Chief of Staff for Revenue and GTM Teams

Retrieved on: 
星期一, 五月 15, 2023
Professional Services, Data Management, Business, Technology, Software, Artificial Intelligence, Cloud, Knowledge, Workflow, Workplace, Synthetic media, Dynamics, ChatGPT, Record, Machine Intelligence Research Institute, Human, ERP, Multimedia, Emotion, Next-best-action marketing, CRM, Generative, Honeywell, DataStax, GTM, Cloud database, Salesforce, Fortune 500, Conference, Automation, Sales, New Relic, Mural, Aviso

Aviso , the only end-to-end AI revenue operating system, announced today the launch of MIKI , the industry’s first AI-powered Chief of Staff for Revenue and GTM teams.

Key Points: 
  • Aviso , the only end-to-end AI revenue operating system, announced today the launch of MIKI , the industry’s first AI-powered Chief of Staff for Revenue and GTM teams.
  • MIKI is a purpose-built, assistive front-end on top of the Aviso platform.
  • MIKI makes accessing, updating and acting on insights from CRM, Cloud Databases, ERP, emails, recorded meetings, and other GTM datasets faster, more conversational, and actionable.
  • MIKI automates Next Best Action synchronized to the individual’s calendar to increase the timing and likelihood of the rep taking action.

Verana Health Research on Missing Data for Diabetic Retinopathy Severity Published in the Journal of the American Medical Informatics Association

Retrieved on: 
星期二, 五月 9, 2023
Science and technology in Asia, Electronic health record, Varnaq, Diabetes, IRIS, Registry, Diabetic retinopathy, American Medical Informatics Association, Missing data, Ophthalmology, Quality of life, American Academy, DR, American Academy of Ophthalmology, Research, Paratriathlon, JAMIA, RWD, Millennium, Machine Intelligence Research Institute, CDC, Journal of the American Medical Informatics Association, Patient, EHR, Visual acuity, Comorbidity, SAN, Korea Disease Control and Prevention Agency, Diagnosis, MPH, ICD-9, Health information management, Disease, Medical device, Dietary supplement, Medical imaging, Vaccine

SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data—today announced its recent ophthalmic research has been published in the peer-reviewed Journal of the American Medical Informatics Association (JAMIA). The study demonstrates how de-identified real-world data (RWD) from electronic health records (EHRs) in medical registries can allow for a deeper understanding of data trends, patterns, or gaps by helping to fill in the missing pieces and providing deeper context.

Key Points: 
  • SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Verana Health ®—a digital health company elevating quality in real-world data—today announced its recent ophthalmic research has been published in the peer-reviewed Journal of the American Medical Informatics Association (JAMIA).
  • Conducted by a team of Verana Health researchers, the study shows a non-random association between missing EHR data regarding the severity of diabetic retinopathy (DR) in de-identified patients and specific demographic, clinical, and practice-level characteristics.
  • Verana Health elevates data quality, which requires understanding how data is recorded by clinicians in the real world, how diagnosis codes are used to capture disease severity, and completeness of the information.
  • This finding supports the assessment that clinical encounters with unspecified disease severity are associated with less severe DR severity.

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

Retrieved on: 
星期六, 五月 6, 2023
IOP, Glaucoma, Refraction, Cataract, American Academy, American Academy of Ophthalmology, Medicine, MIGS, Machine Intelligence Research Institute, American Society of Cataract and Refractive Surgery, Stanford University School of Medicine, MD, Patient, OMNI, FDA, Roger Hawkins (drummer), Society, Pharmaceutical industry, Ophthalmology

Analysis included 16,789 patients in 4 different cohorts: 1) procedures enabled by OMNI® Surgical System technology in combination with cataract 2) iStent Inject® in combination with cataract 3) Hydrus® in combination with cataract or 4) cataract surgery alone.

Key Points: 
  • Analysis included 16,789 patients in 4 different cohorts: 1) procedures enabled by OMNI® Surgical System technology in combination with cataract 2) iStent Inject® in combination with cataract 3) Hydrus® in combination with cataract or 4) cataract surgery alone.
  • This was a statistically significantly greater medication reduction (p
  • The retrospective analysis was performed in partnership with Verana Health, the exclusive end-to-end data curation and analytics partner for the Academy’s IRIS Registry.
  • As physicians, we should be open to tailoring treatment options in a patient-specific way, including offering MIGS as a means for both IOP and medication reduction.

Verana Health's Qdata Geographic Atrophy Links EHR and Imaging Data to Provide a Holistic View of the Patient Journey

Retrieved on: 
星期三, 四月 19, 2023
Choroidal neovascularization, Angiopoietin, Abstract, Injection, ARVO, Medical Affairs Bureau, Commercialization, Paratriathlon, Natural history, IRIS, DME, AMD, Faricimab, Eye, Clinical trial, Geographic atrophy, Quality of life, American Academy, Computer vision, American Academy of Ophthalmology, Research, GA, Medicine, Diabetic retinopathy, Genentech, RWD, Millennium, Diagnosis, Forecasting, Machine Intelligence Research Institute, VEGF, HIV disease progression rates, MD, EHR, Machine learning, Visual acuity, Algorithm, Physician, SAN, OCT, Association for Research in Vision and Ophthalmology, Health information management, Disease, Medical imaging, Pharmaceutical industry, Medical device, Nursing, Ophthalmology, Patient

SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data (RWD)— will announce the development of Qdata® Geographic Atrophy at ARVO 2023, the annual conference of the Association for Research in Vision and Ophthalmology, which takes place in New Orleans between April 23 to 27. This new offering already provides a comprehensive clinical view of real-world data from almost 350,000 de-identified geographic atrophy (GA) patients, making Verana Health the leading company able to identify GA diagnosis from both electronic health records (EHR) and images for research. As Verana Health ingests even more ophthalmic images in 2023, this number will continue to grow.

Key Points: 
  • Combining this image data with EHR data from the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight) will support researchers in gaining a comprehensive view into the GA patient journey.
  • Verana Health is the Academy's exclusive end-to-end data curation and analytics partner for the IRIS Registry.
  • Qdata Geographic Atrophy includes de-identified data from more than 8,000 providers and 2,600 GA patients who have linked images and is rapidly growing.
  • In addition to announcing Qdata Geographic Atrophy with Images at ARVO 2023 , Verana Health will present four abstracts:
    1.

Verana Health Study Using Curated Real-World Data to Replicate Phase III Ophthalmology Clinical Trial Published in OSLI Retina

Retrieved on: 
星期三, 一月 18, 2023
Laser, Eye surgery, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, RWD, VIEW, IRIS, FDA, Regeneron Pharmaceuticals, Research, Isabella Tree, Manuscript, Machine Intelligence Research Institute, Food, Patient, American Academy of Ophthalmology, American Academy, SAN, III, ARVO, Annual general meeting, Medical imaging, Pharmaceutical industry, Retina, Ophthalmology

SAN FRANCISCO, Jan. 18, 2023 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data—today announced that medical journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina has published a manuscript detailing innovative research showing how curated, de-identified real-world data (RWD) from the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight) was used to replicate primary outcome measures of two large-scale randomized controlled trials (RCTs) in ophthalmology—the VIEW 1 and VIEW 2 (VIEW 1/2) pivotal trials.

Key Points: 
  • Verana Health's study is the first to use RWD to replicate outcomes in an ophthalmology phase III pivotal trial.
  • Following the ARVO presentation, Verana Health researchers conducted modeling to determine whether undetected biases had influenced the data.
  • The Verana Health study demonstrates that researchers can replicate Phase III trial outcomes using curated, de-identified RWD that are fit-for-use.
  • To request a copy of the recently published study, conducted by Dr. Leng and a team of Verana Health researchers, visit: https://info.veranahealth.com/view1-view2-manuscript .

Verana Health Receives New Product Innovation Award from Frost & Sullivan for Its VeraQ Population Health Data Engine

Retrieved on: 
星期三, 一月 11, 2023
RWD, EHR, Genomics, SAN, Urology, Acquisition, Patient, Mortality, Overalls, American Academy, Neurology, Frost, Machine learning, Pharmacy, Natural language processing, ROI, RWE, AQUA, Machine Intelligence Research Institute, Medical device, Medical imaging, Pharmaceutical industry, Ophthalmology

SAN ANTONIO, Jan. 11, 2023 /PRNewswire/ -- Recently, Frost & Sullivan analyzed the real-world evidence (RWE) solutions industry and, based on its findings, recognizes Verana Health® with the 2022 North America New Product Innovation Award. The digital health company uniquely leverages its expertise to meet current unmet market needs, cementing its leadership in the RWE solutions space. It delivers quality drug lifecycle and medical practice insights from real-world data (RWD), which is exclusively entrusted to Verana Health by key specialty medical societies, enabling it to manage de-identified data from more than 20,000 healthcare clinicians and more than 70 electronic health record (EHR) systems.

Key Points: 
  • SAN ANTONIO, Jan. 11, 2023 /PRNewswire/ -- Recently, Frost & Sullivan analyzed the real-world evidence (RWE) solutions industry and, based on its findings, recognizes Verana Health ® with the 2022 North America New Product Innovation Award.
  • Verana Health's VeraQⓇ population health data engine transforms structured and unstructured EHR data into curated, quality data (Qdata®) to power insights on care quality, treatment patterns and outcomes, clinical trial site selection, therapeutic market share, and more.
  • For its strong overall performance, Verana Health is recognized with Frost & Sullivan's 2022 North America New Product Innovation Leadership in the RWE solutions industry.
  • Each year, Frost & Sullivan presents this award to the company that develops an innovative element in a product by leveraging leading-edge technologies.

Verana Health Receives New Product Innovation Award from Frost & Sullivan for Its VeraQ Population Health Data Engine

Retrieved on: 
星期三, 一月 11, 2023
RWD, EHR, Genomics, SAN, Urology, Acquisition, Patient, Mortality, Overalls, American Academy, Neurology, Frost, Machine learning, Pharmacy, Natural language processing, ROI, RWE, AQUA, Machine Intelligence Research Institute, Medical device, Medical imaging, Pharmaceutical industry, Ophthalmology

SAN ANTONIO, Jan. 11, 2023 /PRNewswire/ -- Recently, Frost & Sullivan analyzed the real-world evidence (RWE) solutions industry and, based on its findings, recognizes Verana Health® with the 2022 North America New Product Innovation Award. The digital health company uniquely leverages its expertise to meet current unmet market needs, cementing its leadership in the RWE solutions space. It delivers quality drug lifecycle and medical practice insights from real-world data (RWD), which is exclusively entrusted to Verana Health by key specialty medical societies, enabling it to manage de-identified data from more than 20,000 healthcare clinicians and more than 70 electronic health record (EHR) systems.

Key Points: 
  • SAN ANTONIO, Jan. 11, 2023 /PRNewswire/ -- Recently, Frost & Sullivan analyzed the real-world evidence (RWE) solutions industry and, based on its findings, recognizes Verana Health ® with the 2022 North America New Product Innovation Award.
  • Verana Health's VeraQⓇ population health data engine transforms structured and unstructured EHR data into curated, quality data (Qdata®) to power insights on care quality, treatment patterns and outcomes, clinical trial site selection, therapeutic market share, and more.
  • For its strong overall performance, Verana Health is recognized with Frost & Sullivan's 2022 North America New Product Innovation Leadership in the RWE solutions industry.
  • Each year, Frost & Sullivan presents this award to the company that develops an innovative element in a product by leveraging leading-edge technologies.